Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-11-24
Target enrollment:
Participant gender:
Summary
This phase I trial tests the safety, side effects, and best dose of a new drug called
nab-paclitaxel/STI-3031 complex (AP160-complex) in treating patients with solid tumors that
may have spread from where they first started to nearby tissue, lymph nodes, or distant parts
of the body (advanced) or that have spread from where they first started (primary site) to
other distant parts of the body (metastatic). AP160-complex is a combination of the
chemotherapy drug nab-paclitaxel, and the immunotherapy drug STI-3031. Nab-paclitaxel is in a
class of medications called antimicrotubule agents. It works by stopping the growth and
spread of tumor cells. Immunotherapy with monoclonal antibodies, such as STI-3031, may help
the body's immune system attack the cancer, and may interfere with the ability of tumor cells
to grow and spread. AP160-complex may work better than standard therapies in treating
advanced or metastatic solid tumors.